The clinical implications of methylated P15 and P73 genes in adult acute lymphoblastic leukemia

Abstract EN

Background : aberrant methylation of promoter associated CpG islands is an epigenetic modification of DNA which is associated with gene silencing.

It plays an important role in the leukemia pathogenesis.

This phenomenon is frequently observed in acute lymphoblastic leukemia (ALL) and results in the functional inactivation of its associated genes.

The aim of this study is to investigate the frequency and the prognostic impact of p15 and p73 genes methylation in adult acute lymphoblastic leukemia Patients.

Patients and Methods : Methylation-specific polymerase chain reaction (PCR) was used to analyze methylation of the p15 and p73 genes in 51 newly diagnosed adult ALL patients.

Results : the methylation frequencies of p15 and p73 genes at diagnosis were 41.2 % and 27.5 % respectively, while concomitant methylation was detected in 14 % of the patients.

Concomitant methylation of p15 and p73 genes was associated with significant lower rate of CR compared to patients without methylation (57 % versus 90 %), P = 0.008.

Overall survival (OS) was not affected by p15 methylation, but was poorer with p73 methylation and the difference was near significant (p = 0.059).

For patients without methylation, the survival benefit was significant when compared to patients with p15, p73 or both genes methylation (p = 0.047).

The leukemia free survival was not affected by the methylation status of single gene p15 or p73, but tended to be worse in patients with methylated p15, p73 or both genes when compared to patients without methylation (p = 0.08).

Conclusion : aberrant p73 promoter methylation is a potential prognostic factor in adult ALL patients.

P15 methylation is frequent in Egyptian adult ALL patients, its concomitant methylation with p73 is of poor prognostic significance.

Identification of these molecular targets improve risk assessment and selection of appropriate therapy.